Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
|Articles|October 21, 2005
VEGF shows promise in speeding wound healing
Dr. Ferrara's work provided a basis for a major breakthrough in cancer research — the development of an antibody against VEGF in the treatment of lung and colorectal cancer.
Advertisement
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
3
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
4
Alopecia Areata Awareness Month: 2026 in Review
5